8-K: Establishment Labs Reports Q3 2024 Results, Updates Revenue Guidance Amid US Launch Success

Establishment Labs announced its third quarter 2024 financial results, highlighted by a successful US launch of Motiva implants and an updated revenue guidance for the year.

Summary

• Establishment Labs reported a third quarter revenue of $40.2 million, a slight increase from $38.5 million in the same period last year.
• The company's loss from operations improved to $13.1 million, compared to a loss of $21.0 million in the prior year.
• Adjusted EBITDA loss was $7.0 million, a significant improvement from the $16.3 million loss in the same quarter of 2023.
• The company updated its 2024 revenue guidance to $165 million to $168 million, down from the previous range of $174 million to $184 million.
• Cash use for the quarter was $14.9 million, a substantial decrease from $38.0 million in the prior year.
• As of September 30, 2024, the company had a cash balance of $39.7 million, which increases to approximately $114.0 million proforma after including a $25.0 million credit facility draw and $50.0 million from a stock sale.
• The company secured FDA approval for Motiva Implants on September 26, 2024, and expects U.S. revenue to exceed $35 million in 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful US launch and improved financial metrics, but tempered by the lowered revenue guidance and continued losses.

Positives

• The U.S. launch of Motiva implants has exceeded expectations, with rapid adoption by plastic surgeons and women.
• The company has significantly reduced its operating expenses, with SG&A expenses decreasing by approximately $5.9 million and R&D expenses decreasing by approximately $2.3 million compared to the same quarter last year.
• The company's cash position has been strengthened through a recent stock offering and credit facility draw.
• The company has secured an agreement in principle for a $50 million investment in its Chinese distributor, which will support growth in China.
• The company has reduced its net loss to $16.7 million, compared to a net loss of $29.3 million in the year-ago period.

Negatives

• The company has lowered its 2024 revenue guidance from $174 million to $184 million to $165 million to $168 million.
• Gross profit margin decreased to 63.9% from 67.7% in the same quarter last year, primarily due to geographic mix and foreign currency exchange rates.
• The company is still operating at a loss, with a net loss of $16.7 million for the quarter.
• The company's cash balance decreased by $0.3 million from December 31, 2023, before the recent financing activities.

Risks

• The company's future performance is subject to risks and uncertainties, including the rate of adoption of its products, the success of marketing initiatives, and the ability to protect its intellectual property.
• The company faces competition in a rapidly changing environment.
• The company's ability to achieve its financial goals is dependent on its ability to scale operations, manage supply chains, and attract and retain key personnel.
• The company's performance is subject to economic and competitive factors, as well as existing and new regulatory requirements.
• The company's future results may be affected by the timing or amount of various reconciling items that would impact the forward-looking expectations for non-GAAP financial measures.

Future Outlook

The company expects U.S. revenue to exceed $35 million in 2025 and anticipates many years of significant double-digit revenue growth and emerging profitability ahead.

Management Comments

• The U.S. launch of Motiva has exceeded even our high expectations.
• We have onboarded over 250 new accounts in just the first three weeks of our launch and right now, we are adding 15 new accounts a day.
• We have taken this opportunity to strengthen our balance sheet and with the tangible results of reductions in our expense base, we are well funded for the opportunities ahead.
• We continue to focus on efficiencies across our global organization and our EBITDA loss was less than half of what it was a year ago despite increased investment in the United States.
• We are on a clear path for global market leadership and have many years of significant double-digit revenue growth and emerging profitability ahead of us.

Industry Context

The announcement reflects a positive trend in the medical technology sector, particularly in the area of women's health and breast aesthetics. The successful U.S. launch of Motiva implants indicates a strong market demand for innovative and safer implant options. The company's focus on efficiency and cost reduction aligns with broader industry trends towards profitability and sustainable growth.

Comparison to Industry Standards

• Establishment Labs' revenue growth of 4.4% year-over-year is moderate compared to some high-growth medical device companies, but the company is in a growth phase with a new product launch in the US.
• The company's gross profit margin of 63.9% is within the typical range for medical device companies, but the decrease from 67.7% in the prior year is a concern.
• The reduction in operating expenses is a positive sign, as many medical device companies struggle with high operating costs during growth phases.
• The adjusted EBITDA loss of $7.0 million is an improvement, but the company still needs to achieve profitability.
• The successful launch of Motiva in the US is a positive sign, as many medical device companies struggle to gain traction in the US market.
• Competitors such as Allergan (now AbbVie) and Mentor (Johnson & Johnson) have established market positions, but Establishment Labs is differentiating itself with its focus on safety and innovation.

Stakeholder Impact

• Shareholders will be impacted by the updated revenue guidance and the recent stock offering.
• Employees may be affected by the ongoing cost reduction initiatives.
• Customers (plastic surgeons and women) will benefit from the availability of Motiva implants in the U.S.
• Suppliers may be impacted by the company's efforts to optimize its supply chain.
• Creditors will be impacted by the company's debt obligations and credit facility.

Next Steps

• The company will continue to focus on the U.S. launch of Motiva implants.
• The company will continue to focus on efficiencies across its global organization.
• The company will continue to expand its sales team in the U.S., aiming for 40 sales representatives by year-end.
• The company will continue to work towards achieving revenue milestones to access the Tranche D credit facility.
• The company will file its quarterly report on Form 10-Q on November 12, 2024.

Key Dates

Keywords

Motiva Implants, Breast Implants, Medical Technology, Financial Results, Revenue Guidance, FDA Approval, EBITDA, Femtech, Breast Aesthetics, Breast Reconstruction